Who are Placebo cagrilintide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pramlintide acetate (Symlin).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-cagrilintide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Placebo cagrilintide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo cagrilintide (Placebo cagrilintide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amylin receptor agonist. Area: Obesity / Metabolic disease.

phase 3 Amylin receptor agonist Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1) Obesity / Metabolic disease Small molecule Live · refreshed every 30 min

Target snapshot

Placebo cagrilintide (Placebo cagrilintide) — Novo Nordisk A/S. Cagrilintide is an amylin receptor agonist that slows gastric emptying and promotes satiety to reduce appetite and food intake.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo cagrilintide TARGET	Placebo cagrilintide	Novo Nordisk A/S	phase 3	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1)
pramlintide acetate (Symlin)	pramlintide acetate (Symlin)	AstraZeneca	marketed	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amylin receptor agonist class)

AstraZeneca · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo cagrilintide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-cagrilintide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing